Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Olympus receives 510(k) clearance to market Beta-Human Chorionic Gonadotropin assay

Olympus America : 01 October, 2008  (New Product)
Olympus has received 510(k) clearance from the US Food and Drug Administration to market the Beta-Human Chorionic Gonadotropin (Beta-hCG) assay, a test used for the early detection of pregnancy.
The Assay is designed for use with the fully automated AU3000i Immunoassay System.

The appearance of Beta-hCG in serum soon after conception makes it the ideal indicator for the detection and confirmation of pregnancy. Beta-, hCG can be detected in serum as early as six days after conception.

The Olympus Beta-hCG Assay is a two-step paramagnetic particle (Dynabeads) chemiluminescent immunoassay for the diagnostic quantitative determination of total Beta-hCG levels in 50 microlitres of human serum. The Assay is calibrated against the 4th WHO Standard 75/589 for human Beta-hCG, and has an approximate measuring range of 0.05 to 1000 IU/L. For samples with Beta-hCG concentration exceeding 1000 IU/L (1000 mIU/mL), the AU3000i can automatically perform a 1:200 dilution. The test kit contains reagents, as well as a single ready-to-use calibrator and a ready-to-use quality control. Calibration frequency is every 28 days and on-board stability of reagents is also 28 days.

“With this latest FDA clearance, Olympus continues to build its menu of important assays and offers laboratories the ability to process these frequently ordered tests on the high-capacity AU3000i Immunoassay System,” said Lorraine Damico, director of immunoassay marketing for Olympus America.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo